相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Oncolytic Viruses and Immune Checkpoint Inhibition: The Best of Both Worlds
Venkatesh Sivanandam et al.
MOLECULAR THERAPY-ONCOLYTICS (2019)
NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control
Jan P. Boettcher et al.
CELL (2018)
A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments
Kevin C. Barry et al.
NATURE MEDICINE (2018)
Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell Engager
Anna Wing et al.
CANCER IMMUNOLOGY RESEARCH (2018)
WDFY4 is required for cross-presentation in response to viral and tumor antigens
Derek J. Theisen et al.
SCIENCE (2018)
Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells
Maria Carmen Ochoa et al.
IMMUNOLOGY AND CELL BIOLOGY (2017)
Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells
Victor A. Gall et al.
CANCER RESEARCH (2017)
Targeting neoantigens to augment antitumour immunity
Mark Yarchoan et al.
NATURE REVIEWS CANCER (2017)
Neoantigens encoded in the cancer genome
Ton N. Schumacher et al.
CURRENT OPINION IN IMMUNOLOGY (2016)
Expansion and Activation of CD103+ Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition
Helene Salmon et al.
IMMUNITY (2016)
Stable, Nonviral Expression of Mutated Tumor Neoantigen-specific T-cell Receptors Using the Sleeping Beauty Transposon/Transposase System
Drew C. Deniger et al.
MOLECULAR THERAPY (2016)
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Robert H. I. Andtbacka et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Macrophages are critical effectors of antibody therapies for cancer
Kipp Weiskopf et al.
MABS (2015)
Mutant MHC class II epitopes drive therapeutic immune responses to cancer
Sebastian Kreiter et al.
NATURE (2015)
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Eliezer M. Van Allen et al.
SCIENCE (2015)
Neoantigens in cancer immunotherapy
Ton N. Schumacher et al.
SCIENCE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Active secretion of CXCL10 and CCL5 from colorectal cancer microenvironments associates with GranzymeB+ CD8+ T-cell infiltration
Timothy J. Zumwalt et al.
ONCOTARGET (2015)
An HSV-2 based oncolytic virus can function as an attractant to guide migration of adoptively transferred T cells to tumor sites
Xinping Fu et al.
ONCOTARGET (2015)
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
Janis M. Taube et al.
CLINICAL CANCER RESEARCH (2014)
T-Cell and NK-Cell Infiltration into Solid Tumors: A Key Limiting Factor for Efficacious Cancer Immunotherapy
Ignacio Melero et al.
CANCER DISCOVERY (2014)
Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
Gabriela Bindea et al.
IMMUNITY (2013)
Innate and adaptive immune cells in the tumor microenvironment
Thomas F. Gajewski et al.
NATURE IMMUNOLOGY (2013)
The Histone Deacetylase Inhibitor Valproic Acid Lessens NK Cell Action against Oncolytic Virus-Infected Glioblastoma Cells by Inhibition of STAT5/T-BET Signaling and Generation of Gamma Interferon
Christopher A. Alvarez-Breckenridge et al.
JOURNAL OF VIROLOGY (2012)
Incorporation of the B18R Gene of Vaccinia Virus Into an Oncolytic Herpes Simplex Virus Improves Antitumor Activity
Xinping Fu et al.
MOLECULAR THERAPY (2012)
Construction of an Oncolytic Herpes Simplex Virus That Precisely Targets Hepatocellular Carcinoma Cells
Xinping Fu et al.
MOLECULAR THERAPY (2012)
NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors
Christopher A. Alvarez-Breckenridge et al.
NATURE MEDICINE (2012)
Genital HSV-2 Infection Induces Short-Term NK Cell Memory
Mohamed F. Abdul-Careem et al.
PLOS ONE (2012)
Engineered epidermal growth factor mutants with faster binding on-rates correlate with enhanced receptor activation
Jennifer L. Lahti et al.
FEBS LETTERS (2011)
Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action
Lisa DeFazio-Eli et al.
BREAST CANCER RESEARCH (2011)
Expression of HER-2 in MCF-7 breast cancer cells modulates anti-apoptotic proteins Survivin and Bcl-2 via the extracellular signal-related kinase (ERK) and phosphoinositide-3 kinase (PI3K) signalling pathways
Aisha Siddiqa et al.
BMC CANCER (2008)
Natural Killer Cells as Novel Helpers in Anti-Herpes Simplex Virus Immune Response
Subhadra Nandakumar et al.
JOURNAL OF VIROLOGY (2008)
Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses
Giulia Fulci et al.
CANCER RESEARCH (2007)
Differential antigen processing by dendritic cell subsets in vivo
Diana Dudziak et al.
SCIENCE (2007)
Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses
Giulia Fulci et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice
Ann-Charloff Steffen et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2006)
A mutant type 2 herpes simplex virus deleted for the protein kinase domain of the ICP10 gene is a potent oncolytic virus
Xinping Fu et al.
MOLECULAR THERAPY (2006)
Tumor Imaging using a picomolar affinity HER2 binding affibody molecule
A Orlova et al.
CANCER RESEARCH (2006)
Interleukin-15 and natural killer and NKT cells play a critical role in innate protection against genital herpes simplex virus type 2 infection
AA Ashkar et al.
JOURNAL OF VIROLOGY (2003)
Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells
H Wakimoto et al.
GENE THERAPY (2003)
Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect
XP Fu et al.
MOLECULAR THERAPY (2003)
The complement response against an oncolytic virus is species-specific in its activation pathways
H Wakimoto et al.
MOLECULAR THERAPY (2002)
Complex between Peptostreptococcus magnus protein L and a human antibody reveals structural convergence in the interaction modes of Fab binding proteins
M Graille et al.
STRUCTURE (2001)
Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors
JN Parker et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
分享论文
